GMSRX Mutual Fund

NAV$14.81

Fund Essentials - as of Jan 31, 2026

Net Assets
$15M
Expense Ratio
1.01%
Dividend Yield (Current)
1.88%
Holdings
1,943
Inception Date
Mar 9, 2007
Fund Family
Nationwide
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Quarterly

Performance

YTD+17.54%
1 Year+39.56%
3 Year+17.50%
5 Year+6.04%
10 Year+10.66%

Asset Allocation

Stocks: 90.17%
Bonds: 9.78%
Other: 0.05%

Price Chart (6M)

View Full Chart →

Top Holdings

View All →
TickerNameWeight
-Treasury Repurchase Agreement4.65%
-204970758.Srdlc4.01%
-Government Agency Repurchase Agreement 2026-02-022.01%
BEBloom Energy Corporation Class A1.07%
CRDOCredo Technology Group Holding Ltd0.62%
Top 10 Concentration: 14.99%Report Date: Jan 31, 2026
Download all 1943 holdings for GMSRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
1.88%
Frequency
Quarterly
Latest Distribution
$0.00
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

GMSRX Mutual Fund Overview

GMSRX Mutual Fund (Nationwide Small Cap Index Fund Class R) is managed by Nationwide with $14.5M in net assets. GMSRX expense ratio is 1.01%, holding 1943 positions across sectors including Industrials, Health Care, Financials. Inception date: 2007-03-09.

GMSRX performance shows a YTD return of 17.54%. The 1-year return is 39.56% and the 5-year return is 6.04%. GMSRX dividend yield stands at 1.88%, paid quarterly.

GMSRX top holdings include Treasury Repurchase Agreement (4.7%), 204970758.Srdlc (4.0%), Government Agency Repurchase Agreement 2026-02-02 (2.0%), Bloom Energy Corporation Class A (1.1%), Credo Technology Group Holding Ltd (0.6%). View all GMSRX holdings, sector breakdown, or dividend history.

GMSRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. GMSRX alternatives are available via the screener, along with tax-loss harvesting opportunities.